Plasma β-phenylethylamine in Parkinson's disease

Kurume Medical Journal

Volumn 47, Issue 4, 2000, Pages 267-272

  Miura, Yumiko ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical course; Hoehn and Yahr stage; Parkinson' s disease; Plasma phenylethylamine

Indexed keywords

PHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE;

AGED; ARTICLE; BLOOD; FEMALE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGED; PARKINSON DISEASE;

AGED; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PHENETHYLAMINES;

EID: 0034572229     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.47.267     Document Type: Article

References (33)

1. Forno S. Pathology of Parkinson's disease. In: Movement Disorders, Neurology 2, ed. Marsden CD and Fahn S, Butterworth Scientific, London, pp 21-40, 1981.
2. Paterson IA, Jourio AV, and Boulton AA. 2-Phenylethylamine: A modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 1990; 55:1827-1837.
3. Barroso N, and Rodriguez M. Action of β-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission. Euro J Pharmacol 1997; 63:195-203.
4. Dyck LE, Yang CR, and Boulton AA. The biosynthesis of p-tyramine, m-tyramine, and β-phenylethylamine by rat striatal slices. J Neurochem Res 1983; 10:211-220.
5. Jourio AV, Paterson IA, Zhu MY, and Matte G. Electrical stimulation of the substania nigra and changes of 2-phenylethylamine synthesis in the rat striatum. J Neurochem 1991; 56:213-220.
6. Wu PH, and Boulton AA. Metabolism, distribution and disappearance of injected β-phenylethylamine in the rat. Can J Biochem 1975; 53:42-50.
7. Durden DA, and Philips SR. Kinetic measurements of the turnover rates of phenylethylamine and tryptamine in vivo in the rat brain. J Neurochem 1980; 34:1725-1732.
8. Philips SR, and Robson AM. In vivo release of endogenous dopamine from rat caudate nucleus by phenylethylamine. Neuropharmacology 1983; 22:1297-1301.
9. Rao TS, Baker GB, and Coutts RT. N-Dipropargy-2-phenylethylamine, a potentprodrug of 2-phenylethylamine: neurochemical and neurophamacological studies in rat. Brain Res Bull 1987; 19:47-55.
10. Knoll J, Miklya I, Knoll B, Marko R, and Racz D. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sci 1996; 58:2101-2114.
11. Zhou G, Shoji H, Yamada S, and Matsuishi T. Decreased cerebrospinal fluid β-phenylethylamine in Parkinson' s disease. J Neurol Neurosurg Psychiatry 1997; 63:754-758.
12. Hoehn MM, and Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442.
13. Yamada S, Hirano M, Nishi S, Inokuchi T, and Uchimura H. Temperament traits associated with platelet monoamine oxidase activity and plasma 2-phenylethylamine in healthy volunteers. Biogenic Amines 1994; 10:295-302.
14. Nazarari AJ, Baker GB, Coutts RT, Yeung JM, and Rao TS. Rapid analysis of β-phenylethylamine in tissues and body fluids utilizing pentafluorobenzoylation followed by electron-capture gas chromatography. Prog Neuro-Psychopharmacol and Biol Psychiat 1987; 11:251-258.
15. Nakagawara M, Shioe K, and Kariya T. Determination of β-phenylethylamine in plasma by capillary gas chromatography-chemical ionization mass spectrometry. Biogenic Amines 1991; 8:11-17.
16. Durden DA, Philips SR, and Boulton AA. Identification and distribution of β-phenylethylamine in the rat. Can J Biochem 1973; 51:995-1002.
17. Philips SR, Rozdilsky B, and Boulton AA. Evidence for the presence of m-tyramine, typtamine and phenylethylamine in the rat brain and several areas of human brain. Biol Psychiat 1978; 13:51-57.
18. Sabelli HC, Fawcett J, Gusovsky F, Javaid J, Edwards J et al. Urinary phenylacetate: a diagnostic test for depression? Science 1983; 225:1187-1188.
19. Davis BA, and Boulton AA. The trace amines and their acidic metabolites in depression -an overview. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:17-45.
20. Potkin SG, Karoum F, Chuang LW, Cannon-Spoor HE, Phillips I et al. Phenylethylamine in paranoid chronic schizophrenia. Science 1979; 206:470-471.
21. O'Reilly R, Davis BA, Durden DA, Thorpe L, Machnee H et al. Plasma phenylethylamine in schizophrenic patients. Biol Phychiatry 1991; 30:145-150.
22. Yu PH, Bowen RC, Davis BA, and Boulton AA. Platelet monoamine oxidase activity and trace acid levels in plasma of agoraphobic patients. Acta Psychiatry Scand 1983; 67:188-194.
23. Antelman SM, Edwards DL, and Lin M. Phenylethylamine: Evidence for a direct, postsynaptic dopamine receptor stimulating action. Brain Res 1977; 127:317-322.
24. Nakajima T, Kakimoto Y, and Sano I. Formation of alpha phenylethylamine in mammalian tissue and its effect on motor activity in the mouse. J Pharmacol Exp Ther 1964; 143:315-325.
25. Satoi M, Matsuishi T, Yamada S, Yushiro Y, Etsuo O et al. Decreased cerebrospinal fluid levels of β-phenylethylamine in patients with Rett syndrome. Ann Neurol 2000; 47:801-803.
26. Steventon G, Humfrey C, Sturman S, Waring RH, and Williams AC. Monoamine oxidase B and Parkinson's disease. Lancet 1990; 335:180.
27. Mann JJ, Stanley M, Kaplan RD, Sweeney J, and Neophytides A. Central catecholamine metabolism in vivo and the congenitive and motor deficits in Parkinson's disease. J Neurol Neurosurg Psyciatry 1983; 46:905-910.
28. Checkoway H, Costa LG, Woods JS et al. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease. J Neural Transm (P-D sect) 1992; 4:283-290.
29. Kuiper MA, Konings CH, Bergmans PLM, and Wolters EC. Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients. J Neurol Sci 1993; 117:41-45.
30. Steventon GB, Sturman SG, Heafield MTE et al. Platelet monoamine oxidase-B activity in Parkinson's disease. J Neural Transm 1989; 1:255-261.
31. Bonucelli U, Piccini P, Dotto PD et al. Platelet monoamine oxidase B activity in Parkinson's disease. J Neurosurg Psychiat 1990; 53:854-855.
32. Jarman J, Glover V, Sandler M, Turjanski N, and Stern G. Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation. J Neural Transm 1993; 5:1-4.
33. Marsden CD. Parkinson's disease. Lancet 1990; 1:948-952.